Chronic kidney disease and cardiovascular disease by Maharaj, S
Cardiovascular disease (CVD) is the leading cause of death in 
patients with end-stage renal disease (ESRD) worldwide and 
accounts for approximately 30 - 50% of all deaths. It is a sobering 
fact that the risk for premature CVD in a 30-year-old patient with 
ESRD is similar to that of a 70 - 80-year-old without chronic kidney 
disease (CKD).
It is unclear how much of the association between kidney and 
vascular disease results from 
•    vascular disease causing kidney failure 
•    kidney failure causing vascular disease or 
•    the common underlying factors that promote the progression of 
CKD and CVD.
The prevalence of CVD is increased among patients in all stages 
of CKD (Table I) and early CKD is a well-established independent 
risk factor for an adverse cardiovascular outcome (Fig. 1). This 
relationship becomes exponential as glomerular filtration rate 
(GFR) declines below 45 ml/min. Consequently, patients with 
reduced renal function are more likely to die from CVD than they 
are likely to develop ESRD. 
The outlook among the ESRD population is much worse. Only 
16% of new dialysis patients have normal hearts.  On starting 
dialysis therapy, the prevalence of cardiomyopathy is high, as is the 
presence of ischaemic heart disease, left ventricular hypertrophy 
(LVH) and heart failure. This high prevalence of CVD on starting 
dialysis suggests that the predialysis phase of CKD is a state of high 
cardiac risk.
Spec trum of CVD in patients with CKD
The spectrum of cardiac involvement in CKD involves 3 main 
pathological forms: 
•    altered cardiac geometry and mechanics
•    atherosclerosis
•    arteriosclerosis.
Left ventricular (LV) remodelling is pervasive in CKD and is 
due to various genetic, mechanical and neurohormonal factors, 
which alter LV size, shape and function and result in LVH with its 
associated cardiovascular sequelae. As GFR declines the prevalence 
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Table I. Stages of chronic kidney disease
Stage 1: Kidney damage (pathological abnormalities or markers of 
damage including abnormalities in blood or urine tests or in 
 imaging studies) with normal or raised glomerular filtration rate 
(≥ 90 ml/min/1.73 m²)
Stage 2: Glomerular filtration rate 60 – 89 ml/min/1.73 m² with 
evidence of kidney damage
Stage 3: Glomerular filtration rate 30 – 59 ml/min/1.73 m²
Stage 4: Glomerular filtration rate 15 – 29 ml/min/1.73 m²
Stage 5: End-stage renal failure, glomerular filtration rate  
< 15 ml/min/1.73m²
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of LVH increases and is associated with a 
rise in cardiovascular mortality.  
Atherosclerosis of coronary arteries is the 
primary cause of ischaemic heart disease in 
patients with CKD, with acute myocardial 
infarction accounting for 20% of all cardiac 
deaths. The coronary plaque in dialysis 
patients is a more advanced and complex 
lesion, characterised by greater degrees 
of medial thickening and calcification. 
However, a significant number (27 - 50%) of 
patients with ESRD who experience angina 
do not have large-vessel disease. Here, 
microvascular atherosclerosis, severe LVH 
and anaemia are thought to be the causative 
factors. 
Vascular remodelling is a pathological 
hallmark of CKD, affecting the large arteries 
as well as the coronary vessels. In part, this 
is due to medial calcification, which reduces 
compliance and manifests as an increase in 
pulse pressure with systolic hypertension. 
This process contributes to aortic stiffness, 
LVH and myocardial infarction, and parallels 
the increase in cardiovascular morbidity and 
mortality in the CKD patient. 
Cardiovascular risk 
factors in the CKD 
population (Table II) 
Although the association between CKD 
and cardiovascular risk was first shown in 
patients with ESRD, it is now well established 
that overt proteinuria (urine protein > 300 
mg/day), with preserved renal function, is 
an established risk factor for atherosclerotic 
CVD (Fig. 2). Even microalbuminuria 
(urine albumin excretion: 30 - 299 mg/day) 
has been recognised as a simple marker 
of atherosclerosis, and is independently 
predictive of cardiovascular morbidity and 
mortality. Microalbuminuria probably 
reflects subclinical vascular damage in the 
kidneys and other vascular beds, and may 
also signify systemic endothelial dysfunction 
that predisposes to future cardiovascular 
events. 
Furthermore, diabetic patients with ESRD 
have a higher cardiovascular mortality than 
non-diabetic ESRD patients. In fact, up to 
50% of diabetics undergoing pre-transplant 
evaluation will have significant coronary 
artery disease (CAD) (i.e. > 50% stenosis 
in one or more vessels). Diabetes itself 
and non-diabetic CKD share many of the 
pathogenic risk factors that account for this 
excess mortality. These include proteinuria, 
endothelial dysfunction, increased oxidant 
stress and dyslipidaemia (see below). Both 
diabetes and CKD are associated with 
medial calcification, LVH and accelerated 
atherosclerosis. Hence, the combination of 
both diabetes and CKD portends an additive 
poor cardiac risk. This is exemplified 
by studies which have shown that both 
increased carotid intima-media thickness 
and increased aortic stiffness (both of 
which independently predict cardiovascular 
mortality) are more prevalent in diabetic 
CKD than either diabetes or non-diabetic 
CKD alone.
Certain uraemia-related risk factors, such 
as anaemia, altered calcium/phosphate 
homeostasis, vascular inflammation and 
oxidant stress, also contribute to the 
accelerated atherosclerosis and maladaptive 
vascular remodelling among the CKD 
population.
Anaemia in the presence of less severe 
renal dysfunction (creatinine clearance: 
25 - 75 ml/min) is associated with LVH, and 
more severe anaemia in the ESRD patient is 
associated with LV dilation, cardiac failure 
and death. 
The prevalence and severity of cardio-
vascular calcification (CVC) is increased in 
patients with ESRD. The exact mechanism 
is unknown, but an imbalance between 
promoters and inhibitors of calcification is 
postulated (Table III). Aside from traditional 
Framingham risk factors, a high Ca/PO4 
product is a potent promoter of CVC. 
Calcification involves the large arteries, 
coronary vessels and cardiac valves. Medial 
calcification leads to increased pulse pressure, 
increased afterload, reduced coronary 
perfusion, myocardial infarction, cardiac 
failure and death. Valvular calcification may 
lead to stenosis, arrhythmias, heart failure, 
and infective endocarditis.
Attempts to reverse this calcification process 
(with the use of novel phosphate binders and 
calcimimmetics) are still in the experimental 
phases of study.
Vascular remodelling is a pathological 
hallmark of CKD, affecting the large 
















Fig. 2. Proteinuria and relative risk for cardiovascular death.2
Table II. Cardiovascular risk factors in chronic kidney disease
Traditional major risk factors  Factors unique to CKD 
Diabetes     Microalbuminuria/proteinuria
Hypertension    Anaemia
Raised LDL-C    Altered calcium/phosphate homeostasis
Cigarette smoking    Volume overload
Left ventricular hypertrophy  Sympathetic overactivity
     Increased oxidant stress
     Increased vascular inflammation  
     Lp(a)
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Pathogenesis of vascular 
injury in CKD 
In addition to the traditional risk factors, 
accelerated atherosclerosis peculiar to 
CKD involves the three related processes 
of vascular inflammation, oxidative stress 
and vascular calcification, all of which result 
in vascular remodelling. Oxidative stress 
has a central role in the pathogenesis of 
atherosclerosis and CKD is associated with 
an imbalance favouring pro-oxidant over 
antioxidant systems, contributing to the 
increased atherosclerotic burden.  Serum C– 
reactive protein (CRP) is a reliable marker of 
atherosclerotic complications. Both CRP and 
thrombogenic factors, such as fibrinogen, 
are also elevated in patients with ESRD, and 
are strong predictors of death and adverse 
cardiovasular events.
Declining renal function itself is also 
associated with an inflammatory response, 
manifested by an increase in pro-
inflammatory cytokines in both early and 
advanced CKD. Increased levels of the pro-
atherogenic cytokine, IL-6, are indepen-
dently associated with carotid atherosclerosis 
and predict mortality in dialysis patients.
Diagnosis of CVD in the 
CKD patient
Diagnosis is difficult as a significant number 
of patients (up to 50%) are asymptomatic, 
suffering silent ischaemia. This is seen 
particularly in diabetics and the elderly. 
Uraemia itself is known to alter sympathetic 
responses and contributes to the silent 
ischaemia that is often observed in younger 
ESRD patients without diabetes. 
Diagnosis is compounded by the fact that 
exercise electrocardiography is neither 
sensitive nor specific – interpretation is 
hampered by electrolyte abnormalities, 
conduction defects, uraemic pericarditis 
and LVH, all of which distort the baseline 
electrocardiogram. Furthermore, patients 
are often unable to exercise maximally, 
due to peripheral neuropathy, peripheral 
vascular disease and poor effort tolerance.
Therefore, coronary angiography remains 
the gold standard for the detection of 
epicardial CAD, but complication rates tend 
to be higher among the CKD population. 
These include con-trast nephropathy, athero-
embolism, bleed-ing complications and 
contrast-induced pulmonary oedema. In 
the predialysis patient undergoing coronary 
angiography, the risk may be enough to 
precipitate ESRD as a result of the procedure 
itself. 
There are also limitations to angiography. It 
is of little value in diagnosing microvascular 
CAD. Secondly, more than a quarter of ESRD 
patients with typical angina who undergo 
angiography have normal or minimal CAD. 
Consequently, there is still a need for a safe, 
non-invasive, diagnostic modality that 
will allow stratification of cardiovascular 
risk among the CKD population. Here, 
myocardial perfusion studies and 
dobutamine stress echocardiography have 
undergone extensive evaluation among the 
ESRD population. In a recent meta-analysis 
the sensitivity and specificity for both these 
tests in predicting coronary stenoses was 
only about 60%. Therefore a negative study 
should be interpreted with caution in the 
high-risk patient. 
Coronary angiography might be the gold 
standard for the diagnosis of epicardial CAD. 
However, in a resource-limited country 
like South Africa, it may not be feasible to 
subject all medium- and high-risk patients 
to angiography. Furthermore, whether a 
long history of diabetes constitutes high 
risk or not, is debatable, and the decision 
to proceed to angiography may best be 
individualised. Recognising all these 
limitations, our current recommendations 
for the diagnostic evaluation of ischaemia 
in the CKD and ESRD patient employ a risk 
stratification approach (Fig. 3).
In a resource-poor setting like the South 
African state sector, patients with CAD 
are not offered renal replacement therapy 
(RRT), including dialysis or transplantation. 
However, in the authors’ opinion, those 
patients with mild disease (single vessel) 
should be offered a revascularisation 
procedure first, and should then be 
reassessed for transplant suitability. Patients 
with advanced disease (double/triple vessel) 
have significant vascular involvement and 
multisystem disease. As the commonest 
cause of graft loss in these circumstances is 
cardiovascular death, transplantation would 
lead to allograft wastage, and therefore 
cannot be recommended. Palliative dialysis 
then becomes the therapy of choice.
Elderly patients (> 60 years) with ESRD 
have a higher incidence of CVD, and RRT 
is currently an exclusion criterion in the 
South African state sector. Notwithstanding 
the ethical considerations surrounding 
this issue, there are sufficient data available 
to demonstrate that these patients do 
Table III. Novel factors involved in vascular calcification in the CKD 
patient
Promoters     Inhibitors
High Ca/PO4 product    Fetuin A
Uraemic serum     BMP-7
Vitamin D therapy     Matrix gla protein
Hyperparathyroidism    Osteopontin
Chronic inflammation    Osteoprotegerin
LDL-C      HDL
EVALUATION of  ISCHAEMIA 
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Non-invasive testing:
• Exercise / dipyridamole scintigraphy(MIBI-SPECT)
• Dobutamine stress echocardiography
Acute Non acute 
No further evaluation
Positive
Negative and suitable candidate
Aggressive risk factor intervention




Fig. 3. Risk stratification approach to the diagnostic evaluation of ischaemia in the CKD and 
ESRD patient.
l
  CME  August  2007  Vol.25  No.8
pg384-388.indd   386 8/16/07   2:16:47 PM
benefit from renal transplantation. In these 
circumstances the use of marginal kidneys 
may be more appropriate and therefore 
our selection criteria should be expanded 
to accept the so-called elderly onto RRT 
programmes in South Africa.
Newer modalities
Over the last decade, cardiac CT has 
been studied as an alternative to invasive 
coronary angiography in the diagnosis of 
CAD. Although electron beam computed 
tomography (EBCT) cannot detect in-
dividual obstructive lesions, it has a high 
sensitivity for the detection of coronary 
artery calcification (CAC). Among the 
general population, CAC scores correlate 
with plaque burden and vessel stenosis, and 
high scores are predictive of future cardiac 
events. This correlation among the ESRD 
population is less well established. Higher 
CAC scores have been found to be more 
prevalent among patients with stage 3 - 5 
CKD, and rapidly progressive CAC scores 
in the dialysis population is a well-described 
phenomenon. It is not clearly established 
whether a high CAC score represents 
medial vascular calcification associated with 
arteriosclerosis (a feature of CKD) or intimal 
calcification (a feature of atherosclerosis) 
or both. Although total CAC scores do 
correlate with the number and severity of 
angiographically proven diseased vessels, 
there are no long-term follow-up data 
available to determine if increased scores 
correlate with an adverse cardiac outcome.  
A more suitable imaging modality may 
be modern-day 64-slice coronary CT 
scanning. Several recent studies among the 
general population have shown it to have 
an excellent diagnostic accuracy for the 
detection of significant stenosis in even 
the smaller coronary arteries as well as side 
branches, with sensitivities and specificities 
ranging from 86% to 95% and 93% to 97% 
respectively. With a high negative predictive 
value of 95 - 97%, multidetector CT can 
reliably exclude a haemodynamically 
significant stenosis as well.
There have been no published data 
regarding the clinical utility of coronary CT 
angiography in the diagnostic evaluation 
of the patient with CKD. The procedure is 
also not without risk, since it involves the 
injection of contrast. However, in the patient 
on maintenance dialysis, this risk would be 
of little significance.
Since invasive coronary angiography may 
not be accompanied by any percutaneous 
intervention the procedure places patients at 
an unnecessary risk for complications such as 
bleeding, perforation and athero-embolism. 
Coronary CT angiography is not associated 
with these complications, and the promising 
results in the non-ESRD population make it 
an attractive area for future study.
Management of 
cardiovascular risk in the 
CKD/ESRD patient  
(Table IV)
Approximately 75% of patients with CKD 
have hypertension, the prevalence of which 
increases as GFR declines. Since lowering 
blood pressure decreases cardiovasular 
morbidity and mortality and slows CKD 
progression, control of blood pressure to 
target levels is of paramount importance. 
Lower target levels are recommended 
(< 130/80 mmHg) in CKD and even lower 
levels (< 125/75 mmHg) should be attained 
in patients with significant proteinuria. 
To achieve these targets, at least 3 - 4 
medications are often required.
Control of proteinuria and the inhibition of 
the renin-angiotensin system are im-portant 
in slowing the progression of diabetic and non-
diabetic CKD. Whether the renoprotection 
offered by the use of ACE inhibitors and 
angiotensin receptor blockers is due to their 
antihypertensive or antiproteinuric effects, 
or both, is still controversial. However, their 
use is associated with regression of LVH, 
reduction in casdiovascular morbidity and 
mortality, reduction in proteinuria and a 
slower progression to ESRD in diabetic and 
non-diabetic CKD.
Correction of anaemia is associated 
with regression of LVH, resolution of 
angina and a reduction in cardiovascular 
mortality. 
Cardiovascular  disease
Table IV. Targets for risk factor reduction in CKD3
Factor   Target     Recommended therapy 
Hypertension  Proteinuria < 1 g/d: BP < 130/80 mmHg Initially: ACE inhibitor plus salt restriction +   
   Proteinuria > 1 g/d: BP < 125/75 mmHg diuretic. Add angiotensin II receptor blocker   
        or non-dihydropyridine calcium channel   
        blocker. Refer if BP still not controlled 
Proteinuria  < 1 g/d     Use an ACE inhibitor or angiotensin    
        II receptor blocker alone or in combination;   
        titrate to control proteinuria even if blood   
        pressure target is achieved
Blood glucose  Haemoglobin A1C: 7 - 8%   Type 1 DM: insulin    
(in DM)        Type 2 DM: sulphonylureas (GFR > 60 ml/min);  
        biguanides (GFR > 30 ml/min); insulin (GFR    
        < 30 ml/min)
Dyslipidaemia  Total cholesterol < 5.17 mmol/l  Statin       
   LDL cholesterol < 3.10 mmol/l
Anaemia   Maintain haemoglobin above 11 g/dl  Correct haematinic deficiencies    
   Avoid fall below 10 g/dl   Parenteral iron in CKD stage 4 - 5    
        Erythropoietin in CKD stage 4 - 5
Hyperparathyroidism/ Serum calcium > 2.2 mmol/l  Calcium and vitamin D supplementation  
renal osteodystrophy Serum phosphate < 1.8 mmol/l  Reduce phosphate intake to ≈ 800 mg/d   
   Serum PTH between 1 and 2 × normal
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Tight diabetic control not only slows 
progression of diabetic nephropathy, but is 
also associated with a lower risk of macro-
vascular disease, including ischaemic 
heart disease (IHD) and peripheral 
vascular disease. Metformin is of benefit 
for macrovascular disease in obese type 
2 diabetics, but is contraindicated in the 
later stages of CKD (GFR < 30 ml/min).
The direct lipid-lowering effects of statins 
are known to reduce cardiovascular 
risk. However, their pleiotropic 
effects, independent of lipid lowering, 
are postulated to have beneficial 
cardiovascular effects as well. These 
include stabilisation of endothelial 
function and anti-thrombogenic and 
anti-inflammatory properties, thus 
targeting the key factors involved in the 
pathogenesis of atherosclerosis. These 
effects justify their use in CKD patients 
with high cardiovascular risk. 
Correction of anaemia is associated with 
regression of LVH, resolution of angina and 
a reduction in cardiovascular mortality. 
Attention should also focus on controlling 
hyperparathyroidism, which reduces the 
risk of cardiovascular calcification and 
prevents bone marrow fibrosis, which is 
associated with erythropoietin-resistant 
anaemia.  
Summary
The aim of this article is to reinforce the 
importance of early detection of CKD, 
not only to slow the progression to ESRD, 
but also to identify cardiovascular disease, 
the major determinant of mortality 
among the CKD population. Currently 
the management of CKD in South Africa 
is suboptimal – it is hoped that with 
an aggressive multifactorial risk factor 
modification programme coupled with a 
rational pharmacological approach, we 
may halt the devastating course of CKD. 
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In a nutshell 
•    CVD is the leading cause of death in patients with CKD.
•    The risk of CVD increases as CKD progresses to ESRD.
•    Clinicopathological manifestations of CVD in CKD are:
   •    accelerated atherosclerosis
   •    left ventricular hypertrophy
   •    systolic hypertension.
•    ‘Uraemia-related’ risk factors add to the increased CVD risk.
•    Exercise electrocardiography is a suboptimal test for the diagnosis of CVD.
•    Coronary angiography is still the gold standard for diagnosis of CAD.
•    Achieving targets for risk factors in CKD slows progression of CKD and lowers CVD risk.
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Single suture
A glass a day
An Italian study of elderly people suggests that those with mild cognitive impairment should drink a glass of wine a day. The study, a 
longitudinal study of 1 445 ageing Italians who did not have cognitive impairment and 121 with mild cognitive impairment, showed 
that, compared with total abstention, those who drank a glass of wine a day may reduce their progression to full-blown dementia. 
Moderate drinking, defined as less than one glass a day, was also associated with decreased progression to dementia compared with total 
abstention. The study does not say whether red or white wine is preferred.
Solfizzi V, et al. Neurology 2007; 68: 1790-1799.
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